Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, et al. Am J Respir Crit Care Med 2020 Mar 4. doi: 10.1164/rccm.202002-0359.

Read + Share

Amedeo Smart

Independent Medical Education

Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, et al. Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis. Am J Respir Crit Care Med 2020 Mar 4. doi: 10.1164/rccm.202002-0359.
PMID: 32130866